Jefferies Downgrades Leidos to Hold Citing Organic Growth Headwinds

Key Facts

Amid shifting dynamics in the defense and government services sectors, Jefferies has downgraded Leidos Holdings (LDOS) from Buy to Hold, lowering its price target to $140. The downgrade is primarily attributed to limited organic growth prospects and specific concerns regarding the company's health business segment. According to reports, the decision was driven by a downward revision of 2027 earnings estimates and a lower valuation multiple relative to industry peers.

The move comes as defense contractors face varying performance trends; for instance, peer firm Booz Allen Hamilton reported a robust 13.9% revenue increase in its most recent quarter per its earnings release, intensifying the competitive landscape for Leidos. Compared to sector benchmarks, this downgrade reflects analyst caution regarding the company's ability to maintain high margins amidst current growth headwinds, according to market data.

Investors are closely monitoring LDOS price action following the downgrade to see if the stock can maintain its current technical support levels. Looking ahead, the market is focused on the upcoming U.S. Core PCE Price Index release on May 28, 2026, which serves as a critical inflation gauge and could influence broader sentiment for growth stocks and companies reliant on long-term government contracts.